Pharmacotherapy of Alcohol Dependence Department of Surgery Grand Rounds St. Luke’s and Roosevelt Hospitals New York, Wednesday, September 7, 2005 Petros.

Slides:



Advertisements
Similar presentations
Drugs used in the Treatment of Alcohol Abuse/Addiction Tristan Knowles.
Advertisements

Best Practice Tom Shiffler, MD 7/23/10
Drugs For Treating Drug Addiction Barry Zevin MD Tom Waddell Health Center San Francisco Department of Public Health Homeless Programs Board Certified.
Evidence-Based Guidelines for Pharmacotherapy in Alcohol Dependence Chandan Nayak, MD Addiction Fellow University of Michigan Department of Psychiatry.
Drugs used in the Treatment of Alcohol Abuse/Addiction Tristan Knowles.
Pharmacotherapy for Alcohol Dependence Clinical Addiction Research and Education Unit Section of General Internal Medicine Boston University Schools of.
Emergency Psychiatry E. Prost. Outline 1. Emergency Room Assessment 2. Behavioural Emergencies: Assessment 3. Behavioural Emergencies: Interventions.
Mosby items and derived items © 2007 by Mosby, Inc., an affiliate of Elsevier Inc. Chapter 11 Antianxiety Agents.
Prevalence of Alcohol Use Disorders
Copyright Alcohol Medical Scholars Program1 Pathological Gambling and Alcohol Use Disorders Timothy W. Fong MD UCLA Gambling Studies Program Alcohol Medical.
Role of Medications in Recovery and the Prevention of Relapse Mark Publicker, MD FASAM Medical Director, Mercy Recovery Center, Westbrook Maine.
Keri Holmes-Maybank, MD Cathryn Caton, MD, MS MUSC June 21, 2012
Inpatient and Outpatient Management of Alcohol Withdrawal Devang Gandhi, MD Robert Joel Bush, MD University of Maryland- Sheppard Pratt Addiction Medicine.
Drug-Induced Seizures (in 15 minutes or Less) Robert S. Hoffman, MD Director, NYC Poison Center Associate Professor Emergency Medicine and Medicine NYU.
Inpatient Management of Alcohol Withdrawal
Sedative-Hypnotic Drugs and Alcohol
Rapivab™ - peramivir injection
Copyright Alcohol Medical Scholars Program1 The Relationships Between Alcohol Use Disorders and Nicotine Dependence Margaret Rukstalis, M.D. University.
Contemporary Treatments in the Field of Alcohol Misuse Dr Farrukh Alam Consultant Psychiatrist Director of Addictions.
CIWA Protocol: Fraser Health
From screening into treatment: Implementation solutions for Alcoholism therapy Thomas R. Kosten MD JH Waggoner Chair and Professor of Psychiatry & Neuroscience.
New concept – no traditional combination LODOZ contains Bisoprolol and Hydrochlorothiazide in subtherapeutic dosages: - Bisoprolol 2.5 mg (= half / quarter.
BUPRENORPHINE TREATMENT: A TRAINING FOR MULTIDISCIPLINARY ADDICTION PROFESSIONALS Module III – Buprenorphine 101.
LOVE IN THE TIME OF CRYSTAL METHAMPHETAMINE World Psychiatric Association Athens, Greece March 15, 2005 Petros Levounis, M.D. Director, The Addiction.
Psychopharmacology – A brief introduction. Objectives Review general categories of psychiatric disorders Review general categories of psychiatric disorders.
Alcohol Dr Alison Battersby.
Sedatives: Anxiolytics & Alcohol
Dr. Avinash De Sousa.  State government aided hospital.  Private psychiatric set up – nursing home.  Out patient private practice.  Private general.
Pharmacotherapy in Psychotic Disorders. Antipsychotic drugs Treat the symptoms of the disorder Do not cure schizophrenia Include two major classes: –
Alcohol. Plan Role play in small groups Discuss any issues which arise Go through some of the basics Cover the entire “journey”
Drugs used in treatment of addiction
Raymond F. Anton, MD for The COMBINE Study Research Group
The COMBINE Study: Design and Methodology Stephanie S. O’Malley, Ph.D. for The COMBINE Study Research Group JAMA Vol. 295, , 2006 (May 3 rd.
Medical and Specialist Interventions in Alcohol Dependence Peter Rice, Consultant Psychiatrist, NHS Tayside.
Recent Developments in the Pharmacotherapy of Alcoholism Henry R. Kranzler, M.D. Alcohol Research Center Univ. of CT School of Medicine.
Evidence Based Medicine Pharmacological Treatment of Alcohol Dependence.
Pharmacotherapy for Alcohol Dependence
Clinical Management Course: Medical Complications of Alcoholism Peter R. Martin, M.D. Professor of Psychiatry and Pharmacology.
Background and Rationale for COMBINE A Multisite Clinical Trial Sponsored by National Institute on Alcohol Abuse and Alcoholism NIH, DHHS Margaret E. Mattson,
Buprenorphine {Suboxone®, Subutex®}
Management of Substance Use Disorder Module P: Addiction-Focused Pharmacotherapy.
What the National Institute on Drug Abuse’s Clinical Trials Network Can Do for You? Major Findings from Medication Trials and Implications for Community-Based.
ACAMPROSATE Lipha Pharmaceuticals, Inc. May 10, 2002 Psychopharmacologic Drugs Advisory Committee Meeting May 10, 2002 Psychopharmacologic Drugs Advisory.
Randomized Controlled CTN Trial of OROS-MPH + CBT in Adolescents with ADHD and Substance Use Disorders Paula Riggs, M.D., Theresa Winhusen, PhD., Jeff.
Alcohol Use Disorder Management Krishna Khanal MD, R II 11/09/2010.
September 2015 PHARMACOLOGY OF ADDICTIONS.  Understanding the pharmacological basis of medications used to manage dependence  Understanding how pharmacological.
Targeted medication 은 가능한가 ? 알코올 사용장애 환자의 치료 전략으로 건양대학병원 정신과 기 선 완.
Addressing Tobacco Use in Mental Health Settings Pharmacotherapy Materials Prepared By: Center for a Tobacco-Free Finger Lakes University of Rochester.
Samantha Allen PharmD Candidate 2012 Case Presentation April 19, 2012 Alcohol Withdrawal Management.
Medication Assisted Treatment for Opioid Use Disorders
INTRODUCTION Acute alcohol withdrawal syndrome occurs when individuals with alcohol dependency abruptly stop or substantially reduce their alcohol consumption.
Managing Alcohol and Opioid Withdrawals
Long term RX with AD’s 6 months after the initial 12 week RX? Some may need longer treatment Withdraw slowly! (paroxetine and venlafaxine)
December 10, 2015 Arthur Robin Williams MD MBE American Academy of Addiction Psychiatry Division on Substance Abuse Department of Psychiatry, Columbia.
One-Year Post-Treatment COMBINE Study Drinking Outcomes Dennis M. Donovan, Ph.D. for the COMBINE Study Research Group Research Society on Alcoholism Baltimore,
DR. FORRY J.BEN PSYCHIATRIC RESIDENT 1DR. FORRY J.BEN 2015.
Smoking Cessation Medication
screening, brief intervention, and referral to treatment
Drugs used for anxiety and panic disorders
Analysis of Safety and Efficacy of Dexmedetomidine as Adjunctive Therapy for Alcohol Withdrawal in ICU Vincent Rizzo MD MBA FACP Ricardo Lopez MD FCCP.
Alcohol Withdrawal in Acute Care
Chapter 38 Drug Abuse II: Alcohol 1.
Presented by J. Arzaga, MSN, RN
Alcoholism and unhealthy use
Alcohol Use Disorder Assessment & Treatment Strategies
Pharmacologic Interventions for Unhealthy Drinking
Melatonin Director, Depression Clinical and Research Program
Copyright Notice This presentation is copyrighted by the Psychopharmacology Institute. Subscribers can download it and use it for professional use. The.
Medication Assisted Treatment: Changing the Trajectory of the Opioid Epidemic
Copyright Notice This presentation is copyrighted by the Psychopharmacology Institute. Subscribers can download it and use it for professional use. The.
Presentation transcript:

Pharmacotherapy of Alcohol Dependence Department of Surgery Grand Rounds St. Luke’s and Roosevelt Hospitals New York, Wednesday, September 7, 2005 Petros Levounis, M.D. Director, The Addiction Institute of New York Chief, Division of Addiction Psychiatry at St. Luke’s and Roosevelt Hospitals

4 HANDOUTS 1. Mayo-Smith, M.F. (2003). Management of Alcohol Intoxication and Withdrawal. In A. W. Graham, T. K. Shultz, M. F. Mayo-Smith, R. K. Ries, & B. B. Wilford (Eds.), Principles of Addiction Medicine (3 rd ed., pp ). Chevy Chase, Maryland: American Society of Addiction Medicine. 2. Fundamentals of Addiction Medicine 3. Addiction Institute Brochure 4. These slides

OUTLINE 1. Introduction 2. Alcohol Intoxication 3. Alcohol Withdrawal 4. Relapse Prevention 5. Co-Occurring Disorders 6. New Directions

1 INTRODUCTION

Epidemiology 207 million = US Population 207 million = US Population 18 million = Alcohol Use Disorders (9%) 18 million = Alcohol Use Disorders (9%) 8 million = Alcohol Dependence (45%) 8 million = Alcohol Dependence (45%) 2 million = Ever treated (24%) 2 million = Ever treated (24%) 1.2 million = Ever seen an M.D. (60%) 1.2 million = Ever seen an M.D. (60%).6 million = Ever given meds (50%).6 million = Ever given meds (50%) Grant BF et al. Arch Gen Psychiatry. 2004;61:

Neurotransmitter Systems GABA→CNS Inhibition GABA→CNS Inhibition Glutamate→CNS Excitation Glutamate→CNS Excitation Opioid→Euphoria/Reward Opioid→Euphoria/Reward Dopamine→Addiction Dopamine→Addiction Serotonin→Impulsivity Serotonin→Impulsivity

2 ALCOHOL INTOXICATION

Characteristics mg/dLWell-being mg/dLWell-being mg/dLIncoordination mg/dLIncoordination mg/dLAtaxia mg/dLAtaxia mg/dLStage I Anesthesia mg/dLStage I Anesthesia mg/dLComa mg/dLComa mg/dLDeath mg/dLDeath

Pharmacotherapy Use IV thiamine and glucose Use IV thiamine and glucose Do not use ipecac, activated charcoal, caffeine, amphetamines, or flumazenil. Do not use ipecac, activated charcoal, caffeine, amphetamines, or flumazenil. Treatment is supportive. Treatment is supportive.

3 ALCOHOL WITHDRAWAL

Characteristics 1 Following the last drink: Following the last drink: –6 to 24 hours: Autonomic Hyperactivity –24 to 48 hours:Seizures –48 to 96 hours:Delirium tremens “Kindling effect” for seizures. “Kindling effect” for seizures. Older patients are at higher risk of DTs. Older patients are at higher risk of DTs. Typically mild, occasionally severe, rarely fatal. Typically mild, occasionally severe, rarely fatal.

Characteristics 2 Autonomic Hyperactivity with: Autonomic Hyperactivity with: –Reduced GABA activity and –Enhanced glutamate activity.

Characteristics 3 Early signs of withdrawal: Early signs of withdrawal: –Tachycardia –Blood pressure elevation –Sweating –Hyperthermia –Tremor (6 to 8 cycles per second)

Assessment Clinical Institute Withdrawal Assessment for Alcohol (revised). Clinical Institute Withdrawal Assessment for Alcohol (revised). Mayo-Smith MF. JAMA. 1997;278:

CIWA-Ar Categories [ Range of Scores: 0-7* ] Neuropsych. Symptoms Physical Symptoms Perceptual Disturbances CLOUDED SENSORIUM NAUSEA/VOMITINGAUDITORY ANXIETYHEADACHEVISUAL AGITATIONTREMORSTACTILE SWEATS * except 0-4 for sensorium Adapted from

Practice Guidelines Adapted from Mayo-Smith MF. JAMA. 1997;278:

Pharmacotherapy 1 Long-acting benzodiazepines (e.g., chlordiazepoxide) are the treatment of choice. Long-acting benzodiazepines (e.g., chlordiazepoxide) are the treatment of choice. Short-acting benzodiazepines (e.g., lorazepam) are preferred in liver damage and the elderly. Short-acting benzodiazepines (e.g., lorazepam) are preferred in liver damage and the elderly. Anticonvulsants are being studied. Anticonvulsants are being studied. Holbrook AM et al. Can Med Assoc J. 1999;160: Bonnet U et al. J Clin Psychopharmacol. 2003;23:514-9.

Pharmacotherapy 2 For symptom triggered medication, administer every hour when CIWA- Ar >= 9: For symptom triggered medication, administer every hour when CIWA- Ar >= 9: –Chlordiazepoxide50 to 100 mg –Lorazepam 2 to 4 mg –Diazepam 10 to 20 mg Mayo-Smith MF. JAMA. 1997;278:

Pharmacotherapy 3 For standing po chlordiazepoxide: For standing po chlordiazepoxide: –Day 1:50 mgQ 4 hours –Day 2:50 mgQ 6 hours –Day 3:25 mgQ 4 hours –Day 4:25 mgQ 6 hours Garbutt JC et al. JAMA. 1999;281:

Pharmacotherapy 4 For delirium tremens: For delirium tremens: –2 to 4 mg IV lorazepam followed by –1 to 2 mg IV lorazepam every 5 minutes until patient is calm. –Taper slowly over 4 to 5 days. Adopted from Garbutt JC et al. JAMA. 1999;281:

Pharmacotherapy 5 In general, for severe withdrawal: In general, for severe withdrawal: 1.Titrate to light sedation. 2.Have flumazenil ready. 3.Calculate daily dose. 4.Decrease dose by 25% daily.

4 RELAPSEPREVENTION

DISULFIRAM Introduced in 1954

Mechanism of Action Alcohol → Acetaldehyde → Acetate Alcohol → Acetaldehyde → Acetate Disulfiram irreversibly binds to acetaldehyde dehydrogenase inhibiting the metabolism of acetaldehyde to acetate. Disulfiram irreversibly binds to acetaldehyde dehydrogenase inhibiting the metabolism of acetaldehyde to acetate. Acetaldehyde accumulates resulting in a violent reaction (nausea, vomiting, flushing). Acetaldehyde accumulates resulting in a violent reaction (nausea, vomiting, flushing).

Efficacy Double-blind, placebo-control study design is not helpful as both the medication and the placebo pills may (or may not) result in fear of drinking. Double-blind, placebo-control study design is not helpful as both the medication and the placebo pills may (or may not) result in fear of drinking. Most studies are negative, but disulfiram may be helpful in highly structured settings. Most studies are negative, but disulfiram may be helpful in highly structured settings. Fuller RK et al. JAMA. 1986;256:

Dosing and Safety mg daily mg daily. Medication costs approximately $40 a month. Medication costs approximately $40 a month. Some liver toxicity; liver function should monitored. Some liver toxicity; liver function should monitored. Inhibits hepatic microsomal enzymes and increases drug levels. Inhibits hepatic microsomal enzymes and increases drug levels. Physician’s Desk Reference. 59 th ed. Pp

NALTREXONE Introduced in 1995

Mechanism of Action Reduces positive reinforcement (reward craving). Reduces positive reinforcement (reward craving). The patient does not experience the full euphorogenic/reinforcing effect of alcohol. The patient does not experience the full euphorogenic/reinforcing effect of alcohol. Prevents a slip from becoming a full-blown relapse. Prevents a slip from becoming a full-blown relapse.

Efficacy Effective in reducing relapse to heavy drinking ( >4 in men, >3 drinks/day in women). Effective in reducing relapse to heavy drinking ( >4 in men, >3 drinks/day in women). The Srisurapanont (2005) meta- analysis found efficacy up to 12 weeks but not after 12 weeks. The Srisurapanont (2005) meta- analysis found efficacy up to 12 weeks but not after 12 weeks. Medication compliance may be a limiting factor in treatment. Medication compliance may be a limiting factor in treatment. Mason BJ. Eur Neuropsychopharmacol. 2003;13: Srisurapanont M & Jarusuraisin N. Cochrane Database Syst Rev 2005.

Dosing and Safety 50 mg daily. 50 mg daily. Medication costs $103 a month. Medication costs $103 a month. Liver toxicity; liver function should monitored closely. Liver toxicity; liver function should monitored closely. Otherwise safe and well-tolerated. Otherwise safe and well-tolerated. No significant drug-drug interactions. No significant drug-drug interactions.

ACAMPROSATE Introduced in 2005

Mechanism of Action Reduces negative reinforcement (abstinence craving). Reduces negative reinforcement (abstinence craving). Neuroadaptation and upregulation of the glutamate system in alcoholism. Neuroadaptation and upregulation of the glutamate system in alcoholism. Acamprosate interferes with the glutamatergic system. Acamprosate interferes with the glutamatergic system.

Efficacy Effective in improving abstinence. Effective in improving abstinence. The Mann et al (2004) meta- analysis found a 50% improvement in 6-month abstinence (36% acamprosate vs. 23% placebo). The Mann et al (2004) meta- analysis found a 50% improvement in 6-month abstinence (36% acamprosate vs. 23% placebo). Three times a day dosing may compromise compliance. Three times a day dosing may compromise compliance. Sass et al. Arch Gen Psychiatry. 1996;53: Mann K et al. Alcohol Clin Exp Res. 2004;28:51-63.

Dosing and Safety 666 mg three times a day. 666 mg three times a day. Medication costs $110 a month. Medication costs $110 a month. Excreted by the kidneys - No liver metabolism. Excreted by the kidneys - No liver metabolism. Mild diarrhea (16% acamprosate vs. 10% placebo). Mild diarrhea (16% acamprosate vs. 10% placebo). No drug-drug interactions. No drug-drug interactions. Physician’s Desk Reference. 59 th ed. Pp

5 CO-OCCURRING DISORDERS

In General Co-occurring alcohol dependence and other psychiatric disorder(s) typically require treatment for both (all). Co-occurring alcohol dependence and other psychiatric disorder(s) typically require treatment for both (all). Treating patients under one roof improves both addiction and mental health outcomes. Treating patients under one roof improves both addiction and mental health outcomes. Mariani JJ, Levin FR. Harvard Rev Psychiatry. 2004;12: Kranzler HR, Jaffe JH. In: Graham TK et al, eds. Principles of Addition Medicine. 3 rd ed. Chevy Chase, MD: American Society of Addition Medicine. 2003:

Depression Antidepressants typically improve depressive symptoms. Antidepressants typically improve depressive symptoms. However, they have limited impact on alcohol use. However, they have limited impact on alcohol use. Nunez EV, Levin FR. JAMA. 2004;291:

Antidepressants’ Effect on Depression From Nunez EV, Levin FR. JAMA. 2004;291:1893.

Antidepressants’ Effect on Substance Use From Nunez EV, Levin FR. JAMA. 2004;291:1893.

6 NEW DIRECTIONS

New Delivery Systems Long-acting naltrexone injection: 100 μm diameter microspheres composed of naltrexone and PLG polymeric matrix. Long-acting naltrexone injection: 100 μm diameter microspheres composed of naltrexone and PLG polymeric matrix. Nausea, headache, and fatigue are the prominent adverse effects. Nausea, headache, and fatigue are the prominent adverse effects. FDA decision expected in late ‘05. FDA decision expected in late ‘05. Please note: This agent is not approved by the FDA for use in alcohol dependence.

Injectable Naltrexone Heavy drinking days rates during a 24 week treatment trial with injectable naltrexone 190 mg and 380 mg Qmonth. Heavy drinking days rates during a 24 week treatment trial with injectable naltrexone 190 mg and 380 mg Qmonth. Injectable naltrexone reduced the rate of heavy drinking by 25% ( P =.02). Injectable naltrexone reduced the rate of heavy drinking by 25% ( P =.02). Adapted from Garbutt et al. JAMA. 2005;293:1622.

New Combinations Acamprosate and naltrexone have different mechanisms of action and may work synergistically. Acamprosate and naltrexone have different mechanisms of action and may work synergistically. The COMBINE trial (n=1,375; 11 sites) will assess the medication combination and two behavioral interventions for a total of 9 possible treatment formulations. The COMBINE trial (n=1,375; 11 sites) will assess the medication combination and two behavioral interventions for a total of 9 possible treatment formulations. COMBINE Study Research Group. Alcohol Clin Exp Res. 2003;27:

Naltrexone/Acamprosate Abstinence rates during a 12-week treatment trial with naltrexone 50 mg QD and acamprosate 666 mg TID. Abstinence rates during a 12-week treatment trial with naltrexone 50 mg QD and acamprosate 666 mg TID. The combination of the two medications helped alcoholics stay abstinent ( P= 0.002) better than each drug alone. The combination of the two medications helped alcoholics stay abstinent ( P= 0.002) better than each drug alone. Adapted from Kiefer F et al. Arch Gen Psychiatry. 2003;60:96.

New Pharmacological Agents Anticonvulsants Anticonvulsants –Topiramate –Carbamazepine –Valproic Acid GABA agonist GABA agonist –Baclofen Selective Serotonin Reuptake Inhibitors Selective Serotonin Reuptake Inhibitors Serotonin (5-HT 3 ) antagonist Serotonin (5-HT 3 ) antagonist –Ondansetron Please note: These agents are not approved by the FDA for use in alcohol dependence.

Where you can find us You can request an addiction consultation by contacting: You can request an addiction consultation by contacting: –Galen Cooper, Ph.D., x38409/pgr at Roosevelt, or –Raisa Montalvo, M.A., x31743/pgr at St. Luke’s. Our website: Our website: Our 24-hour-line: Our 24-hour-line: